

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM829363

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Enzo Clinical Labs, Inc.		07/24/2023	Corporation: NEW YORK
Enzo Biochem, Inc.		07/24/2023	Corporation: NEW YORK
RECEIVING PARTY DATA			
Name:	Laboratory Corporation of America Holdings		
Street Address:	531 South Spring Street		
City:	Burlington		
State/Country:	NORTH CAROLINA		
Postal Code:	27215		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 6			
Property Type	Number	Word Mark	
Registration Number:	2350099	ENZO CLINICAL LABS	
Registration Number:	7037582	LAB TESTING AT THE CLICK OF A BUTTON	
Registration Number:	5839530	EZINTERFACE	
Registration Number:	5461127	YOUR NEIGHBORHOOD LAB	
Registration Number:	3002409	ENZODIRECT	
Registration Number:	6673206	GOTESTMENOW	
CORRESPONDENCE DATA			
Fax Number:	3366077500		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	3366077300		
Email:	fwaldbaum@kilpatricktownsend.com		
Correspondent Name:	William Bryner		
Address Line 1:	1001 West Fourth Street		
Address Line 4:	Winston-Salem, NORTH CAROLINA 27101		
ATTORNEY DOCKET NUMBER:	1232228		
NAME OF SUBMITTER:	Tiffani D. Otey		
SIGNATURE:	/Tiffani D. Otey/		

OP \$165.00 2350099

DATE SIGNED:

08/03/2023

Total Attachments: 16

source=Project Eagle - IP Agreement (Executed)#page1.tif
source=Project Eagle - IP Agreement (Executed)#page2.tif
source=Project Eagle - IP Agreement (Executed)#page3.tif
source=Project Eagle - IP Agreement (Executed)#page4.tif
source=Project Eagle - IP Agreement (Executed)#page5.tif
source=Project Eagle - IP Agreement (Executed)#page6.tif
source=Project Eagle - IP Agreement (Executed)#page7.tif
source=Project Eagle - IP Agreement (Executed)#page8.tif
source=Project Eagle - IP Agreement (Executed)#page9.tif
source=Project Eagle - IP Agreement (Executed)#page10.tif
source=Project Eagle - IP Agreement (Executed)#page11.tif
source=Project Eagle - IP Agreement (Executed)#page12.tif
source=Project Eagle - IP Agreement (Executed)#page13.tif
source=Project Eagle - IP Agreement (Executed)#page14.tif
source=Project Eagle - IP Agreement (Executed)#page15.tif
source=Project Eagle - IP Agreement (Executed)#page16.tif

INTELLECTUAL PROPERTY AGREEMENT

This INTELLECTUAL PROPERTY AGREEMENT (“IP Agreement”), effective as of July 24, 2023, (the “Effective Date”) is made and entered into by and among Enzo Clinical Labs, Inc. a New York corporation (“Enzo Clinical Labs”), Enzo Biochem, Inc., a New York corporation (“Enzo Biochem”) (each, an “Enzo Entity” and, collectively, the “Enzo Entities”) and Laboratory Corporation of America Holdings, a Delaware corporation and its Affiliates (“Labcorp”). Each Enzo Entity and Labcorp is referred to herein as a “Party” and, collectively, as the “Parties”. Capitalized terms used but not defined herein shall have the meanings given to them in the APA (as defined below).

WHEREAS, the Enzo Entities and Labcorp entered into that certain asset purchase agreement dated as of March 16, 2023 (the “APA”), pursuant to which Enzo Clinical Labs agreed to sell the Acquired Assets to Labcorp on the terms and conditions set forth therein;

WHEREAS, the Enzo Entities are the owners of the Acquired Intellectual Property Assets, and the Enzo Entities desire to transfer the Acquired Intellectual Property Assets to Labcorp and Labcorp desires to acquire the Acquired Intellectual Property Assets from the Enzo Entities at Closing;

WHEREAS, the Enzo Entities are the owners of the trade names and trademarks ENZO LABS, ENZO CLINICAL LABS, and GOTESTMENOW, which are part of the Acquired Intellectual Property Assets, and which are used in connection with the Business, and Enzo Entities are the owners of certain trademarks included the Acquired Intellectual Property Assets (these registered and unregistered marks are collectively referred to as the “Trademarks” and identified in the attached Schedule A to this IP Agreement);

WHEREAS, the Enzo Entities wish to assign to Labcorp all federal and common law and other rights, title, and interests in and to the Trademarks for use in connection with the Business (including all the goodwill of the Business symbolized thereby and associated therewith) and Labcorp desires to receive the same, and the Parties wish to record such assignment with the relevant trademark offices;


WHEREAS, Enzo Biochem wishes to continue use of the mark ENZO, but not the trademarks ENZO LABS, ENZO CLINICAL LABS, or GOTESTMENOW, in connection with its other ventures, excluding clinical labs and the commercialization of goods and services exclusively offered by the Business;

WHEREAS, the Enzo Entities are the owners of the domain names “enzoclinicallabs.com”, “enzodirect.com” and “gotestmenow.com,” and variations thereof which are used in connection with the Business, and which Labcorp desires to receive in order to re-direct customers of the Business to Labcorp’s equivalent offerings (hereinafter, the “Domain Names, also identified on Schedule A to the IP Agreement”);

WHEREAS, the Enzo Entities wish to assign the Domain Names to Labcorp for the

purpose recited above;

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1. Each Enzo Entity, on behalf of itself and any applicable Affiliates thereof, hereby conveys, assigns, and transfers to Labcorp all of their right, title and interest in and to the Acquired Intellectual Property Assets, including, without limitation, the Trademarks and Domain Names set forth on Schedule A, all federal and common law and other rights to the Trademarks and the goodwill of the Business associated therewith, and, to the extent they exist, all rights therein provided by international conventions and treaties, all rights of priority and renewals, and all rights to sue, counterclaim and recover damages for past, present and future infringement, dilution, misappropriation, unlawful imitation or other violation thereof or conflict therewith. Each Enzo Entity shall execute the Confirmatory Trademark Assignment set forth as Schedule B-1, and Enzo Biochem shall cause its Affiliate, Enzo Life Sciences, Inc., a New York corporation, to execute the Confirmatory Trademark Assignment substantially in the form attached hereto as Schedule B-2. Each Enzo Entity, on behalf itself and its Affiliates, hereby authorizes and requests the trademark office to record Labcorp as the owner of the Trademarks.
2. Each Enzo Entity, on behalf of itself and any Affiliates thereof, shall immediately cease all use of the Trademarks, including ceasing any use of the Trademarks for any marketing, promotion and advertising of any business and ceasing use of the business entity name Enzo Clinical Labs. Each Enzo Entity shall refrain from any use and/or registration of the trademarks ENZO CLINICAL LABS and ENZO LABS, any use of "Labs" in any combination with "Enzo" but shall maintain the right to use and register the ENZO trademark only with the Excluded Business, as that term is defined in the APA, and other businesses not reasonably considered competitive with the Business.
3. Each Enzo Entity, on behalf of itself and any Affiliates thereof, agrees that it shall not object to or challenge Labcorp's use or registration of the Trademarks in connection with the Business.
4. Labcorp shall not object to or challenge Enzo Biochem's and/or any of its Affiliate's use or registration of the ENZO trademark in connection with any business other than the Business, including without limitation the Excluded Business. Immediately after Closing, Labcorp shall cease using the name "Enzo" other than as part of the names ENZO LABS or ENZO CLINICAL LABS and shall cease all use of the Enzo logo, , in any manner.
5. Each Enzo Entity, on behalf of itself and any Affiliates thereof, agrees to execute and deliver at the reasonable request of Labcorp, all papers, instruments, and assignments, and to perform other reasonable and necessary acts in order to vest all of each Enzo Entity's rights, title, and interest in and to the Acquired Intellectual Property Assets in Labcorp,

including, without limitation, the Confirmatory Trademark Assignment Agreement attached as Schedule B to this IP Agreement. Each Enzo Entity and Labcorp shall use commercially reasonable efforts to (i) take actions necessary or appropriate to consummate the transactions contemplated by this IP Agreement, and (ii) from time to time, execute and deliver such other documents, certificates, agreements and other writings, and take such other actions as may be reasonably necessary in order to consummate or evidence or implement expeditiously the transactions contemplated by this IP Agreement; provided, that, as between the Parties, Labcorp shall be responsible for the preparation of any such documents and other instruments that may be necessary to record and/or perfect Labcorp's right, title and interest in and to the Acquired Intellectual Property Assets (including, without limitation, with any applicable Governmental Authorities), and for any and all costs, expenses and fees associated therewith.

6. Enzo Biochem, on behalf of itself and any Affiliates thereof, hereby unconditionally and irrevocably covenants not to sue Labcorp or its Affiliates for infringement of any existing patent or any patent issuing from a currently pending patent application or from a later filed patent application claiming priority directly or indirectly, to any currently pending patent application owned as of Closing, by Enzo Biochem or its current Affiliates for Labcorp's performance of methods or processes, or the provision of services in Labcorp's operation of the Business after Closing. This covenant not to sue shall run with the relevant patents referenced above such that future assignees, owners, or other right holders of such patents shall likewise be subject to the covenant not to sue with respect to the patents. This IP Agreement may be executed and delivered in counterpart signature pages executed and delivered via electronic mail, and any such counterpart executed and delivered via electronic mail will be deemed an original for all intents and purposes. For the avoidance of doubt, the covenant not to sue shall not apply to, and nothing herein grants any license or other rights with respect to any Intellectual Property held by Seller Parent or its Affiliates for products, including, without limitation, reagents, probes, antibodies, dyes and the GENFLEX equipment that, prior to the Closing, were procured by Seller from Seller Parent or its Affiliates.
7. Enzo Biochem and its Affiliates covenant not to seek patent protection for any inventions included within the Acquired Intellectual Property Assets.
8. The following miscellaneous provisions shall apply to this IP Agreement.
 - a) Any term or provision of this IP Agreement that is invalid or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this IP Agreement or affecting the validity or enforceability of any of the terms or provisions of this IP Agreement in any other jurisdiction. If any provision of this IP Agreement is deemed unenforceable, such provision shall be deemed to be reformed and modified to the minimum amount required to make such provision enforceable.

b) This IP Agreement is for the sole benefit of the Parties and their respective successors and permitted assigns and is not for the benefit of any third party. This IP Agreement shall be binding upon the Parties and their respective successors and permitted assigns.

c) Each Enzo Entity, on behalf of itself and any Affiliates thereof, and Labcorp warrant that the individual(s) whose signature(s) appears below has/have been duly authorized to sign this IP Agreement and bind their respective entity hereto.

d) The Parties agree that they have been represented by counsel during the negotiation, preparation and execution of this IP Agreement, and therefore waive the application of any Law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the Party drafting such agreement or document.

e) No amendment of any provision of this IP Agreement shall be valid unless the same shall be in writing signed by the Parties.

[Signature Pages Follow]

IN WITNESS WHEREOF, the duly authorized representatives of the Parties have caused this IP Agreement to be duly executed and delivered as of the date first written above.


ASSIGNOR:

ENZO CLINICAL LABS, INC.

By:  _____
Name: Hamid Erfanian
Title: Chief Executive Officer
Date: July 24, 2023

ASSIGNOR:

ENZO BIOCHEM, INC.

By:  _____
Name: Hamid Erfanian
Title: Chief Executive Officer
Date: July 24, 2023

LABCORP:

LABORATORY CORPORATION OF AMERICA HOLDINGS

By: _____
Name:
Title:
Date:

Signature Page to Intellectual Property Agreement

IN WITNESS WHEREOF, the duly authorized representatives of the Parties have caused this IP Agreement to be duly executed and delivered as of the date first written above.

ASSIGNOR:

ENZO CLINICAL LABS, INC.

By: _____

Name:

Title:

Date:

ASSIGNOR:

ENZO BIOCHEM, INC.

By: _____

Name:

Title:

Date:

LABCORP:


LABORATORY CORPORATION OF AMERICA HOLDINGS

By: Sandra D. van der Vaart

Name: Sandra D. van der Vaart

Title: Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary

Date: 07/21/2023



Schedule A to IP Agreement

Trademarks

Registered Trademarks

Citation	USPTO Status and Date	Goods and Services	Owner
ENZO CLINICAL LABS App 75741692 Reg 2350099	USPTO Status: Registered and renewed USPTO Status Date: 09-JUN-2020 App 25-JUN-1999 Pub 22-FEB-2000	INT. CL. 42 MEDICAL CLINICAL LABORATORIES	ENZO BIOCHEM, INC. NEW YORK CORPORATION 527 MADISON AVENUE NEW YORK, NEW YORK, 10022
LAB TESTING AT THE CLICK OF A BUTTON App 90250762 Reg 7037582	USPTO Status: Registered and Active USPTO Status Date: 25-APR-2023 App 13-OCT-2020 Pub 15-JUN-2021	INT. CL. 44 CLINICAL TESTING SERVICES IN THE NATURE OF MEDICAL TESTING FOR DIAGNOSTIC OR TREATMENT PURPOSES	ENZO LIFE SCIENCES Suite 3 81 Executive Boulevard Farmingdale, NEW YORK UNITED STATES 11735
EZINTERFACE App 88297699 Reg 5839530	USPTO Status: Registered and Active USPTO Status Date: 20-AUG-2019 App 12-FEB-2019 Pub 4-JUN-2019	INT. CL. 42 PROVIDING TEMPORARY USE OF NON-DOWNLOADABLE SOFTWARE FOR USE IN AUTOMATIC PRINTING OF MEDICAL LABORATORY TEST RESULTS AND NETWORKING FOR ORDERING MEDICAL LAB TESTS AND MEDICAL LAB TEST RESULTS	ENZO BIOCHEM, INC. NEW YORK CORPORATION 527 MADISON AVENUE NEW YORK, NEW YORK, 10022
YOUR NEIGHBORHOOD LAB App 87726094 Reg 5461127 (Supplemental)	USPTO Status: Registered and Active USPTO Status Date: 1-MAY-2018 App 19-DEC-2017 Pub 1-MAY-2018	INT. CL. 42 CLINICAL LABORATORY SERVICES	ENZO BIOCHEM, INC. Suite 3 81 Executive Blvd Farmingdale, NEW YORK UNITED STATES 11735
ENZODIRECT App 76571399 Reg 3002409	USPTO Status: Registered and Renewed USPTO Status Date: 30-APR-2015 App 22-JAN-2004 Pub 26-OCT-2004	INT. CL. 9 ELECTRONIC PROVISION OF MEDICAL, CLINICAL, AND DIAGNOSTIC TEST ORDERING AND TEST RESULT REPORTING INFORMATION SERVICES BETWEEN HEALTH CARE INDUSTRY CONSUMERS AND A CLINICAL LABORATORY VIA LOCAL AND GLOBAL SERVERS	ENZO BIOCHEM, INC. Suite 3 81 Executive Blvd Farmingdale, NEW YORK UNITED STATES 11735
GOTESTMENOW App 90108341 Reg 6673206	USPTO Status: Registered USPTO Status Date: 15-MAR-2022 App 12-AUG-2022 Reg 15-Mar-2022	INT. CL. 44: CLINICAL TESTING SERVICES IN THE NATURE OF MEDICAL TESTING FOR DIAGNOSTIC OR TREATMENT PURPOSES	ENZO LIFE SCIENCES Suite 3 81 Executive Boulevard Farmingdale, NEW YORK UNITED STATES 11735

Common Law Trademarks

- ENZO LABS
- GOTESTMENOW

Domain Names

- enzoclinicallabs.com
- enzodirect.com
- gotestmenow.com

Schedule B-1 to IP Agreement

CONFIRMATORY TRADEMARK ASSIGNMENT

This CONFIRMATORY TRADEMARK ASSIGNMENT (“Trademark Assignment”), effective as of the last dated signature below (the “Effective Date”), is made and entered into by and between Enzo Biochem, Inc., a New York corporation (“Enzo Biochem” or “Assignor”) and Laboratory Corporation of America Holdings, a Delaware corporation (“Labcorp” or “Assignee”). Assignor and Assignee are referred to individually as a “Party” and collectively as the “Parties”.

WHEREAS, Assignor and Assignee have entered into those certain Asset Purchase Agreement and Intellectual Property Agreement contemporaneously herewith pursuant to which Assignee is acquiring assets of Assignor, including, without limitation, certain trademarks owned by Assignor;

WHEREAS, Assignor is the owner of certain of the Trademarks as defined in the Intellectual Property Agreement, including both registered and common law trademarks, and trademark registration identified in the attached Schedule A (collectively, the “Trademarks”);

WHEREAS, Assignor wishes to assign to Assignee all rights, title, and interests in and to the Trademarks (including all goodwill symbolized thereby and associated therewith), and the Parties wish to record such assignment with the relevant trademark offices:

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1. Assignor hereby assigns and transfers to Assignee, its successors and assigns, and Assignee hereby accepts and receives, all of Assignor’s entire rights, title, and interests in, to and under the Trademarks, including, without limitation, (a) the goodwill of the business symbolized by and associated with the Trademarks; and (b) any and all powers and rights of Assignor under the Trademarks, including without limitation, legal actions and rights and remedies at law or in equity for past, present, or future infringements, dilutions, or other violations of the Trademarks, including without limitation, the right to sue for, collect, and retain all damages, profits, proceeds, and all other remedies associated therewith.
2. Assignor hereby authorizes and requests the trademark office to record Assignee as the assignee and owner of the Trademarks.
3. This Assignment will be binding upon and enforceable against Assignor and Assignor’s respective successors and assigns and will inure to the benefit of and be enforceable by Assignee and its successors and assigns.
4. This Assignment may be executed in digital or electronic form (including via .pdf signature) and in any number of counterparts, and by the Parties in separate counterparts, each of which will be deemed an original for all purposes and all of which together will constitute one and the same instrument.

IN WITNESS WHEREOF, the duly authorized representatives of the Parties have caused this Assignment to be duly executed and delivered as of the date first written above.

ASSIGNOR:

ENZO BIOCHEM, INC.

By:  _____
Name: Hamid Erfanian
Title: Chief Executive Officer
Date: July 24, 2023

ASSIGNEE:

LABORATORY CORPORATION OF AMERICA HOLDINGS

By: _____
Name:
Title:
Date:

IN WITNESS WHEREOF, the duly authorized representatives of the Parties have caused this Assignment to be duly executed and delivered as of the date first written above.

ASSIGNOR:

ENZO BIOCHEM, INC.

By: _____

Name:

Title:

Date:

ASSIGNEE:


LABORATORY CORPORATION OF AMERICA HOLDINGS

By: Sandra D. van der Vaart

Name: Sandra D. van der Vaart

Title: Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary

Date: 07/21/2023



Schedule A to Confirmatory Trademark Assignment

Citation	USPTO Status and Date	Goods and Services	Owner
ENZO CLINICAL LABS App 75741692 Reg 2350099	USPTO Status: Registered and renewed USPTO Status Date: 09-JUN-2020 App 25-JUN-1999 Pub 22-FEB-2000	INT. CL. 42 MEDICAL CLINICAL LABORATORIES	ENZO BIOCHEM, INC. NEW YORK CORPORATION 527 MADISON AVENUE NEW YORK, NEW YORK, 10022
EZINTERFACE App 88297699 Reg 5839530	USPTO Status: Registered and Active USPTO Status Date: 20-AUG-2019 App 12-FEB-2019 Pub 4-JUN-2019	INT. CL. 42 PROVIDING TEMPORARY USE OF NON-DOWNLOADABLE SOFTWARE FOR USE IN AUTOMATIC PRINTING OF MEDICAL LABORATORY TEST RESULTS AND NETWORKING FOR ORDERING MEDICAL LAB TESTS AND MEDICAL LAB TEST RESULTS	ENZO BIOCHEM, INC. NEW YORK CORPORATION 527 MADISON AVENUE NEW YORK, NEW YORK, 10022
YOUR NEIGHBORHOOD LAB App 87726094 Reg 5461127 (Supplemental)	USPTO Status: Registered and Active USPTO Status Date: 1-MAY-2018 App 19-DEC-2017 Pub 1-MAY-2018	INT. CL. 42 CLINICAL LABORATORY SERVICES	ENZO BIOCHEM, INC. Suite 3 81 Executive Blvd Farmingdale, NEW YORK UNITED STATES 11735
ENZODIRECT App 76571399 Reg 3002409	USPTO Status: Registered and Renewed USPTO Status Date: 30-APR-2015 App 22-JAN-2004 Pub 26-OCT-2004	INT. CL. 9 ELECTRONIC PROVISION OF MEDICAL, CLINICAL, AND DIAGNOSTIC TEST ORDERING AND TEST RESULT REPORTING INFORMATION SERVICES BETWEEN HEALTH CARE INDUSTRY CONSUMERS AND A CLINICAL LABORATORY VIA LOCAL AND GLOBAL SERVERS	ENZO BIOCHEM, INC. Suite 3 81 Executive Blvd Farmingdale, NEW YORK UNITED STATES 11735

Schedule B-2 to IP Agreement

CONFIRMATORY TRADEMARK ASSIGNMENT

This CONFIRMATORY TRADEMARK ASSIGNMENT (“Trademark Assignment”), effective as of the last dated signature below (the “Effective Date”), is made and entered into by and between Enzo Life Sciences, Inc. a New York corporation (“Enzo Life Sciences” or “Assignor”) and Laboratory Corporation of America Holdings, a Delaware corporation (“Labcorp” or “Assignee”). Assignor and Assignee are referred to individually as a “Party” and collectively as the “Parties”.

WHEREAS, Assignor’s Affiliate, Enzo Biochem, Inc. (“Enzo Biochem”) and Assignee have entered into those certain Asset Purchase Agreement and Intellectual Property Agreement contemporaneously herewith pursuant to which Enzo Biochem agrees to cause Assignor to assign to Assignee a certain trademark owned by Assignor;

WHEREAS, Assignor is the owner of the trademark registration identified in the attached Schedule A (the “Trademark”);

WHEREAS, Assignor wishes to assign to Assignee all rights, title, and interests in and to the Trademark (including all goodwill symbolized thereby and associated therewith), and the Parties wish to record such assignment with the relevant trademark offices.


NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1. Assignor hereby assigns and transfers to Assignee, its successors and assigns, and Assignee hereby accepts and receives, all of Assignor’s entire rights, title, and interests in, to and under the Trademark, including, without limitation, (a) the goodwill of the business symbolized by and associated with the Trademark; and (b) any and all powers and rights of Assignor under the Trademark, including without limitation, legal actions and rights and remedies at law or in equity for past, present, or future infringements, dilutions, or other violations of the Trademark, including without limitation, the right to sue for, collect, and retain all damages, profits, proceeds, and all other remedies associated therewith.
2. Assignor hereby authorizes and requests the trademark office to record Assignee as the assignee and owner of the Trademark.
3. This Assignment will be binding upon and enforceable against Assignor and Assignor’s respective successors and assigns and will inure to the benefit of and be enforceable by Assignee and its successors and assigns.
4. This Assignment may be executed in digital or electronic form (including via .pdf signature) and in any number of counterparts, and by the Parties in separate counterparts, each of which will be deemed an original for all purposes and all of which together will constitute one and the same instrument.

IN WITNESS WHEREOF, the duly authorized representatives of the Parties have caused this Assignment to be duly executed and delivered as of the date first written above.

ASSIGNOR:

ENZO LIFE SCIENCES, INC.

By:  _____
BF5578BE7704460...

Name: Hamid Erfanian
Title: Chief Executive Officer
Date: July 24, 2023

ASSIGNEE:

LABORATORY CORPORATION OF AMERICA HOLDINGS

By: _____

Name:
Title:
Date:

IN WITNESS WHEREOF, the duly authorized representatives of the Parties have caused this Assignment to be duly executed and delivered as of the date first written above.

ASSIGNOR:

ENZO LIFE SCIENCES, INC.

By: _____

Name:

Title:

Date:

ASSIGNEE:


LABORATORY CORPORATION OF AMERICA HOLDINGS

By: Sandra D. van der Vaart

Name: Sandra D. van der Vaart

Title: Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary

Date: 07/21/2023



Schedule A to Confirmatory Trademark Assignment

Citation	USPTO Status and Date	Goods and Services	Owner
LAB TESTING AT THE CLICK OF A BUTTON App 90250762 Reg 7037582	USPTO Status: Registered and Active USPTO Status Date: 25- APR-2023 App 13-OCT-2020 Pub 15-JUN-2021	INT. CL. 44 CLINICAL TESTING SERVICES IN THE NATURE OF MEDICAL TESTING FOR DIAGNOSTIC OR TREATMENT PURPOSES	ENZO LIFE SCIENCES Suite 3 81 Executive Boulevard Farmingdale, NEW YORK UNITED STATES 11735
GOTESTMENOW App 90108341 Reg 6673206	USPTO Status: Registered and Active USPTO Status Date: 15- MAR-2022 App 12-AUG-2022 Pub 17-NOV-2020	INT. CL. 44: CLINICAL TESTING SERVICES IN THE NATURE OF MEDICAL TESTING FOR DIAGNOSTIC OR TREATMENT PURPOSES	ENZO LIFE SCIENCES Suite 3 81 Executive Boulevard Farmingdale, NEW YORK UNITED STATES 11735